4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
27.28 ^USD	+10.00%		+13.86%	+34.65%

May. 15	Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
May. 09	4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

4D Molecular Therapeutics Appoints John F. Milligan as Executive Chairman of Board of Directors

September 08, 2020 at 07:00 am EDT

4D Molecular Therapeutics announced the appointment of John F. Milligan, Ph.D. as Executive Chairman of the Board of Directors. Prior to joining 4DMT, Dr. Milligan had a 29-year career with Gilead, retiring as President and Chief Executive Officer in December 2018.

Latest news about 4D Molecular Therapeutics, Inc.

Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM	May. 14
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	Apr. 15	MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	Apr. 15	MT
Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing	Apr. 04	MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating	Apr. 01	MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating	Apr. 01	MT
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis	Mar. 28	MT
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	Mar. 28	CI
Transcript : 4D Molecular Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM	Mar. 13
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024	Feb. 12	CI
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing	Feb. 08	MT
4D Molecular Therapeutics Launches $250 Million Stock Offering	Feb. 05	MT
4D Molecular Therapeutics Shares Surge on Positive Data From Phase 2 Study of Wet AMD Drug Candidate	Feb. 05	MT
Top Midday Gainers	Feb. 05	MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating	Feb. 05	MT
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05	RE
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell	Feb. 05	MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk	Feb. 05	MT
Transcript : 4D Molecular Therapeutics, Inc. - Special Call	Feb. 05

Chart 4D Molecular Therapeutics, Inc.

Duration

Period

More charts

Company Profile

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - European Cystic Fibrosis Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for 4D Molecular Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.8 USD

Average target price

52.3 USD

Spread / Average Target

+110.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
4D MOLECULAR THERAPEUTICS, INC.	+34.65%	1.28B
MODERNA, INC.	+55.70%	55.7B
LONZA GROUP AG	+41.08%	39.91B
IQVIA HOLDINGS INC.	-5.39%	39.57B
CELLTRION, INC.	-5.56%	28.16B
ICON PUBLIC LIMITED COMPANY	+16.46%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	18.94B
MEDPACE HOLDINGS, INC.	+33.03%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.85%	12.12B
BIO-TECHNE CORPORATION	+2.72%	12.12B

Other Biotechnology & Medical Research